The European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, Valneva and Pfizer’s Lyme disease vaccine candidate. While Valneva’s shares jumped on the news, Pfizer’s stock impact remains uncertain and hinges on European approval and commercialization. The milestone de-risks the program and could unlock royalties or licensing opportunities if Europe approves the vaccine.
Pfizer posted Q2 earnings of $0.77 per share on $15.03 billion in sales, ahead of estimates for $0.69 and $14.41 billion. The results reinforce momentum in Pfizer's portfolio and could support near-term upside for PFE shares amid a broad market rally driven by tech leadership. Investors will scrutinize forward guidance and product mix updates for visibility on 2024–2025 profitability.
Pfizer reported a Q2 profit beat fueled by robust Eliquis demand, underscoring the drug as a core earnings pillar. If Eliquis sustains its growth, Pfizer could see continued profitability and potential upside to guidance in the near term. Investors will watch Eliquis dynamics and broader margin trends to gauge sustained momentum.
Pfizer reported that its oral candidate for vitiligo achieved color restoration in two late-stage trials, clearing a key clinical hurdle and paving the path to regulatory submissions. If regulators accept the data, the therapy could become a new growth driver for Pfizer, contingent on safety outcomes and labeling decisions, and may influence near-term sentiment around PFE.
Pfizer said the FDA granted priority review to its expanded approval application for a prostate cancer treatment combination. This regulatory designation could accelerate labeling and early revenue if data support a larger indication. The article did not disclose specific indications, data details, or the expected decision timing.
Pfizer has temporarily discontinued Premarin vaginal cream in India, a product used for managing menopause symptoms. The move reduces available estrogen therapy options for millions of Indian women and could weigh on Pfizer's near-term sales in the Indian market until a reinstatement or alternate supply is announced.
